Results 81 to 90 of about 26,315,175 (213)
MET, the product of the c-MET proto-oncogene, and its ligand hepatocyte growth factor/scatter factor (HGF/SF) control survival, proliferation and migration during development and tissue regeneration. HGF/SF-MET signaling is equally crucial for growth and
Meyer T. +7 more
core +1 more source
YTHDF2 in hepatocellular carcinoma: Bridging m6A modification and cancer progression
Abstract YTH N6‐methyladenosine RNAbinding protein F2 (YTHDF2) is an N6‐methyladenosine (m6A) reader protein that mainly regulates the stability of methylated transcripts through mRNA decay. In the liver, YTHDF2 is involved in metabolic homeostasis, oxidative stress responses, and immune regulation.
Sijie Zang +7 more
wiley +1 more source
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern +11 more
wiley +1 more source
The MET oncogene encodes the receptor for HGF/Scatter Factor, known to control cell motility and invasion in epithelial cells, We report that the Met/HGF receptor, absent in differentiated adult skeletal muscles, is aberrantly expressed in clinical ...
Scotlandi K +9 more
core +1 more source
Phagocytosis activity is retained by JMML macrophages and increased by CD47 inhibition
Summary Juvenile myelomonocytic leukaemia (JMML) is a childhood myeloid malignancy driven by RAS (rat sarcoma viral oncogene homolog) pathway mutations, characterized by myeloid cell accumulation and organ infiltration. We investigated how clonal macrophage polarization, phagocytic function and CD47 (cluster of differentiation 47) expression contribute
Jun Wang +11 more
wiley +1 more source
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source
Opposing roles of acid phosphatase 1 (ACP1) and ACP3 in prostate cancer progression
Objectives To evaluate the roles of intracellular acid phosphatase 1 (ACP1) and ACP3 expression as biomarkers of prostate cancer progression through a systematic review and meta‐analysis assessing associations with disease presence, tumour aggressiveness, and patient prognosis.
Alessandra V. de S. Faria +3 more
wiley +1 more source
Using the Infinium MethylationEPIC v2.0 array and Heidelberg Brain Tumor Classifier v12.8, 24 international laboratories achieved highly reproducible CNS tumor classification (97.9% correct; median β‐correlation r = 0.99), while copy number variation interpretation showed substantial interlaboratory variability, highlighting the need for harmonized CNV
Katrin Mauch‐Mücke +50 more
wiley +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source

